Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

5.030 +0.020 (+0.40%)
Streaming Delayed Price Updated: 10:07 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
Shareholders should contact the firm as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata regains full development rights to certepetide in the Greater China Region 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details ↗
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement. 
Via Stocktwits
Topics Workforce
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027. 
Via Chartmill
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapy 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.